OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
757556

Amed Co Ltd

Medical Equipment, Supplies & DistributionVerified

Amed Co Ltd has a debt-to-equity ratio of 1.27, indicating a moderate reliance on debt financing relative to equity. The company's liquidity is assessed as medium, with a negative net cash position after subtracting total debt, suggesting potential short-term liquidity constraints. In terms of profitability, Amed Co Ltd's operating cash flow of TWD 18.88 million indicates positive cash generation from operations, though the magnitude is relatively modest given the company's revenue of TWD 821.96 million. The company's capital expenditure of TWD -27.14 million suggests a net outflow for investment in long-term assets, which may support future growth but could also pressure short-term liquidity. Amed Co Ltd's revenue is derived from three main segments: wound care, pain-free medical, and medical device support. The company operates both domestically and internationally, though the input data does not specify the geographic breakdown of revenue. The lack of detailed geographic exposure data limits the ability to assess regional concentration risk. The company's growth trajectory is not explicitly quantified in the input data, but the presence of three distinct business platforms suggests a diversified approach to market expansion. The outlook for the current fiscal year is not provided, but the company's recent financial performance indicates a need to balance investment in growth initiatives with maintaining liquidity. Amed Co Ltd's risk assessment highlights medium liquidity risk and low dilution risk. The company's debt structure, with long-term debt of TWD 505.23 million, suggests a focus on long-term financing. The absence of dilution risk indicates that the company has not issued additional shares recently, and there is no indication of imminent share issuance. Recent events, such as filings or transcripts, are not detailed in the input data, limiting the ability to assess the company's strategic direction or operational developments. The company's financial disclosures provide a baseline for understanding its capital structure and liquidity position, but more granular data is required for a comprehensive analysis.

30-day price · 7575-7.25 (-26.7%)
Low$18.80High$27.20Close$19.90As of15 May, 00:00 UTC
Profile
CompanyAmed Co Ltd
Ticker7575.TWO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Amed Co Ltd is a Taiwan-based company engaged in medical-related business, operating three main platforms: wound care, pain-free medical, and medical device support.

Classification. Amed Co Ltd is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92.

Amed Co Ltd has a debt-to-equity ratio of 1.27, indicating a moderate reliance on debt financing relative to equity. The company's liquidity is assessed as medium, with a negative net cash position after subtracting total debt, suggesting potential short-term liquidity constraints. In terms of profitability, Amed Co Ltd's operating cash flow of TWD 18.88 million indicates positive cash generation from operations, though the magnitude is relatively modest given the company's revenue of TWD 821.96 million. The company's capital expenditure of TWD -27.14 million suggests a net outflow for investment in long-term assets, which may support future growth but could also pressure short-term liquidity. Amed Co Ltd's revenue is derived from three main segments: wound care, pain-free medical, and medical device support. The company operates both domestically and internationally, though the input data does not specify the geographic breakdown of revenue. The lack of detailed geographic exposure data limits the ability to assess regional concentration risk. The company's growth trajectory is not explicitly quantified in the input data, but the presence of three distinct business platforms suggests a diversified approach to market expansion. The outlook for the current fiscal year is not provided, but the company's recent financial performance indicates a need to balance investment in growth initiatives with maintaining liquidity. Amed Co Ltd's risk assessment highlights medium liquidity risk and low dilution risk. The company's debt structure, with long-term debt of TWD 505.23 million, suggests a focus on long-term financing. The absence of dilution risk indicates that the company has not issued additional shares recently, and there is no indication of imminent share issuance. Recent events, such as filings or transcripts, are not detailed in the input data, limiting the ability to assess the company's strategic direction or operational developments. The company's financial disclosures provide a baseline for understanding its capital structure and liquidity position, but more granular data is required for a comprehensive analysis.
Key takeaways
  • Amed Co Ltd maintains a debt-to-equity ratio of 1.27, indicating a moderate reliance on debt financing.
  • The company's operating cash flow of TWD 18.88 million supports its operations but is relatively modest compared to its revenue.
  • Amed Co Ltd's capital expenditure of TWD -27.14 million suggests investment in long-term assets, which may support future growth.
  • The company's liquidity is assessed as medium, with a negative net cash position after subtracting total debt.
  • Amed Co Ltd's risk assessment indicates low dilution risk and medium liquidity risk.
  • The company's business is diversified across three platforms, but detailed geographic exposure data is not provided.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$822.0M
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow$18.9M
CapEx-$27.1M
Free cash flow
Total assets
Total liabilities$744.6M
Total equity$397.0M
Cash & equivalents
Long-term debt$505.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash-$505.2M
Current ratio
Debt/Equity1.3
ROA
ROE
Cash conversion
CapEx/Revenue-3.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric7575Activity
Op margin13.3% medp25 5.9% · p75 13.5%
Net margin8.6% medp25 2.7% · p75 12.7%
Gross margin64.0% medp25 60.1% · p75 65.6%
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-3.3%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity127.0%69.3% medp25 63.4% · p75 74.5%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-03 23:48 UTC#5f3582dc
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 23:50 UTCJob: 1568a868